Sporothrix Antibody, Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Aiding in the diagnosis of extracutaneous sporotrichosis
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Sporothrix Ab, S
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 1 mL
Forms: If not ordering electronically, submit a General Request Form (Supply T239) with the specimen.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross reject
Mild OK; Gross reject
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Serum||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Sporotrichosis is an endemic fungal infection caused by the dimorphic fungus Sporothrix schenckii. Most cases of sporotrichosis have been reported from the subtropical and tropical regions of the Americas, but a global distribution is likely. The organism is often isolated from soil, plants, or plant products (wood), and occupational or recreational exposure to these materials is often implicated in infected individuals.
Infections due to Sporothrix schenckii can be differentiated into several distinct syndromes:
-The cutaneous form of the disease is most common, often arising from sites of minor skin trauma. The primary erythematous, papulonodular lesion may range from several millimeters to 4 cm in size. Secondary lesions develop proximally along lymphatic channels. These generally painless lesions usually do not involve lymph nodes, although lymphadenopathy may develop.
-Extracutaneous sporotrichosis can be manifested as osteoarticular involvement of a single joint. Major joints of the extremities (ankle, knee, elbow, hand) are most often involved. The affected joint is swollen and painful, with an attendant effusion. Systemic symptoms are minimal.
-Pulmonary sporotrichosis with cavitary lesions also has been described.
-A multifocal extracutaneous syndrome has been described, consisting of multijoint involvement, or widely scattered cutaneous lesions. Constitutional symptoms (fever, weight loss) are often noted, and spread to bone and central nervous system may occur. Underlying immune system suppression is often a contributing factor. Untreated infection is ultimately fatal.(1)
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Extracutaneous infections, including disseminated and articular infections, produce positive tests. The test should be positive in approximately 90% to 95% of all primary sporotrichosis infections. Specimens from these patients may become positive by 2 weeks after infection and are not expected to remain positive for more than 7 months after the original primary infection.
Agglutination titers of > or =1:8 indicate presumptive evidence of sporotrichosis. Titers of 1:4 to 1:8 are commonly seen in normal persons.
Some cutaneous infections are associated with negative serologic results.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
A negative test does not exclude the possibility of sporothrix infection since the test is only positive in the early stages of infection.
The presence of high titers of rheumatoid factor in the patient specimen may cause false-positive reactions.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Rex JH, Okhuysen PC: Sporothrix schenckii. In Principles and Practice of Infectious Diseases. Edited by GL Mandell, RG Douglas, JE Bennet. Philadelphia, Churchill Livingstone, 2000, pp 2695-2699
2. Blumer SO, Kaufman L, Kaplan W, et al: Comparative evaluation for 5 serological methods for the diagnosis of sporotrichosis. App Microbiol 1973 July;26(1):4-8
Method Description Describes how the test is performed and provides a method-specific reference
The test is based upon the principle that latex particles sensitized with sporothrix antigens are agglutinated by antibodies that are specific for those antigens. Antibodies against sporothrix of the IgM class are most effective as agglutinins. Results of the latex agglutination test are available within minutes, as compared to 24 to 48 hours for other serological procedures. Due to the type of test procedure (slide agglutination), immunoglobulins other than IgM are not efficiently detected because of the minimum interparticle distance in the suspension and the molecular dimensions of the other immunoglobulins (IgG, IgA, etc.) are not sufficiently large to span the distance efficiently.(Package insert: LA-SPORO Antibody System, Immuno-Mycologics, Inc., Norman, OK; Blumer SO, Kaufman L, Kaplan W, et al. Comparative evaluation for 5 serological methods for the diagnosis of sporotrichosis. Appl Microbiol. 1973 July;26:4-8)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday, Wednesday, Friday; 9 a.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Same day/1 day
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|9673||Sporothrix Ab, S||13273-8|